
Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.
Visiox is a privately funded biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapeutic candidates. Founded with a mission to address highly prevalent eye diseases that lack effective treatment options, Visiox aims to revolutionize the standard of care in ophthalmology. The company focuses on creating advanced solutions to enhance patient and physician satisfaction, positioning itself as a leader in the ophthalmic market.
Notable figures affiliated with Visiox include experienced professionals in the biopharmaceutical industry, although specific names are not provided. The company has achieved significant milestones in its pipeline development, contributing to its growing reputation in the field. By advancing new treatments for common eye conditions, Visiox is making a substantial impact on improving patient outcomes and setting new benchmarks in ophthalmic care.

Visus Therapeutics
visustx.com

Imagen Biotech

Ocular Therapeutix
ocutx.com

Visum Pharma
visumpharmainc.com

EyeCyte
eyecyte.com

Vitreoretinal Technologies

Visgenx
visgenx.com

Aurion Biotech
aurionbiotech.com

Ocular Science
ocularscience.com

Iview Therapeutics

Qlaris Bio
qlaris.bio

Nexis Vision

Oculogenex
oculogenex.com

Hyperion DeFi
eyenovia.com

Ocumension Therapeutics
Companies similar to Visiox include Visus Therapeutics, Imagen Biotech, Ocular Therapeutix and Visum Pharma.
Visiox was founded in 2022.
Visiox's headquarters is located in Tarrytown, NY, US.
Visiox's most recent funding round was for $7M (USD) in August 2022.
As of Aug 3, 2022, Visiox has raised a total of $7M (USD).
Visiox has 7 employees as of Feb 5, 2024.